Pharmaceutical firms to improve deferred accounts receivable portfolios

Domestic pharmaceutical firms are making desperate efforts to shorten the settlement period of their deferred accounts receivables in a bid to cope with protracted business slump and create better management conditions.

Business sources said that a lot of pharmaceutical companies have adopted a variety of payment tools (e.g., cash, issuing of bill and credit cards), while providing i...